Walk into any interventional cardiology conference, and you’ll hear fierce debates: self‑expanding or balloon‑expandable valves? Both have die‑hard fans. The transcatheter aortic valve replacement market research shows that balloon‑expandable valves (like Edwards’ SAPIEN) hold the larger share due to decades of clinical data. They’re precise and work well in calcified annuli.

But self‑expanding valves (Medtronic’s Evolut) are catching up. They’re delivered in a collapsed state and expand on their own, which can be gentler on the anatomy. Plus, they often have a lower profile, allowing access through smaller arteries. The TAVR market trends indicate that next‑gen self‑expanding valves also have repositioning and retrieval features — a game‑changer for tricky cases.

Which is better? It depends on the patient. For bicuspid valves or heavy calcium, some data favors self‑expanding. For straightforward anatomy, balloon‑expandable is faster. Many heart teams now keep both on the shelf.

The winner? Patients. More options mean better outcomes. And with TAVR now approved for low‑risk patients, the market is just getting started.